2022_Oct_PODD_Boston_ Skyscraper2

advanced search

Ophthalmic Drug Delivery54

Issue No #54  January 30th, 2015


Download PDF


Inside the magazine

SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
OCULAR
Dr Shikha P Barman
Integral BioSystems
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
Shikha Barman reviews approaches for delivering drugs for diseases of the back of the eye, and introduces EySite-InjecT™.
PSIVIDA AND OPHTHALMIC DRUG DELIVERY
OCULAR
Dr Paul Ashton
EyePoint Pharmaceuticals
PSIVIDA AND OPHTHALMIC DRUG DELIVERY
Paul Ashton describes how much of the progress that has been made recently in the treatment of ophthalmic diseases can be ascribed to effective drug delivery systems, and outlines some of the delivery technologies and resulting products for which pSivida has been responsible.
MODELLING OCULAR DELIVERY USING COMPUTATIONAL FLUID DYNAMICS
OCULAR
Dr Marc Horner
ANSYS, Inc
MODELLING OCULAR DELIVERY USING COMPUTATIONAL FLUID DYNAMICS
Paul Missel and Marc Horner describe the use of computational fluid dynamics simulations to predict drug flow and temperature inside the eye, and provide examples of applications modelling.
HUGE THERAPEUTIC ADVANCES: BIGGER DRUG DELIVERY OPPORTUNITIES
EXPERT VIEW
Dr Paul Ashton
HUGE THERAPEUTIC ADVANCES: BIGGER DRUG DELIVERY OPPORTUNITIES
Paul Ashton gives an introduction into the current state of the ophthalmics market.
AN INTEGRATED PIPELINE OF OPHTHALMIC PRODUCTS BASED ON EYESOL™ DELIVERY TECHNOLOGY
OCULAR
Dr Dieter Scherer
Novaliq
AN INTEGRATED PIPELINE OF OPHTHALMIC PRODUCTS BASED ON EYESOL™ DELIVERY TECHNOLOGY
Dieter Scherer describes two of Novaliq’s most advanced products: NovaTears®, a wetting agent for the ocular surface, and CyclASol®, a clear formulation of Cyclosporin A. Both products use Novaliq’s semifluorinated alkane technology, EyeSol®.
OCULAR DRUG DELIVERY TECHNOLOGIES: EXCITING TIMES AHEAD
EXPERT VIEW
Dr Ilva D Rupenthal
OCULAR DRUG DELIVERY TECHNOLOGIES: EXCITING TIMES AHEAD
Ilva Rupenthal gives a sector overview of the occular drug delivery space.
EXCIPIENT SELECTION FOR OPHTHALMIC OINTMENTS
OCULAR
Dr Janice Cacace
CoreRx
EXCIPIENT SELECTION FOR OPHTHALMIC OINTMENTS
Janice Cacace and Travis Webb describe the physical properties of petrolatums as they relate to the comfort and efficacy of formulations of ophthalmic ointments.
COMPANY SHOWCASE: GRAYBUG
Michael O'Rourke
Graybug
COMPANY SHOWCASE: GRAYBUG
GrayBug is advancing ophthalmic therapeutics through a continuum of polymerbased drug delivery platforms and innovative products offering sustained competitive advantage.
Top